Abstract
The increasing research about comorbidity shows the growing importance of this topic in the current development of psychiatry. The mayority of these papers discuss the importance of psychological treatment in these kind of patients, but there are a few number dealing with the pharmacological treatment. There are some references on the benefit of the atypical neuroleptics in the treatment of schizophrenic patients using cannabis. The aim of the present paper is trying to verify this hypothesis. Material and Methods: Three groups of patients with paranoid schizophrenia, two of them cannabis users, were included in this study. We made a one year follow-up after treatment with a classic (group ED) or an atypical (group AT) neuroleptic treatment Results: Group AT shows a lower frequency of cannabis use and a greater insight. Conclusions: Atypical neuroleptics could be useful in the management of schizophrenic patients with current cannabis use.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
